Pharmaron Beijing Co., Ltd. has issued the Notice of Annual General Meeting (AGM) for 2025, detailing 15 resolutions to be decided on 12 June 2026 at Juhui Hall, Zhaolin Plaza, Beijing.

Key ordinary resolutions to be voted by non-cumulative poll: • 2025 Board work report. • 2025 profit distribution and 2026 interim dividend plan. • Adoption of the 2025 annual report and results announcement. • Director remuneration for 2026 and a new remuneration management policy for directors and senior management. • 2026 hedging quota approval. • Engagement of domestic and international auditors for the 2026 financial year. • Appointment of a non-executive director for the fourth board session.

Cumulative-voting items: • Election of three executive directors—Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei. • Election of three independent non-executive directors—Ms. Li Lihua, Prof. Tsang King Fung and Ms. Shen Rong.

Special resolutions: • 2026 external guarantees quota. • General mandate for new securities issuance. • Increase in registered capital. • Amendments to the Articles of Association.

Share registration timetable: • H-shareholders must lodge transfer documents by 16:30 on 8 June 2026 to qualify for AGM participation. • The register of members will be closed from 9 June 2026 to 12 June 2026. • Subject to dividend approval, shareholders on record after market close on 15 July 2026 will receive the payout. The register will close from 9 July 2026 to 15 July 2026 for dividend entitlement.

Voting at the AGM will be conducted by poll, and results will be published on the websites of the Hong Kong Stock Exchange and Pharmaron.